In an eight-week study of obese nonhuman primates (n=6 per group), adding the Activin E-targeting antibody IBIO-610 to semaglutide reduced the lean mass fraction of total weight lost from 22% to 6%, with fat accounting for 93% of weight loss versus 77% with semaglutide alone. A single intravenous dose produced a 97% reduction in serum active Activin E at week 8 and a 33.2-day half-life, which the company projects could support twice-yearly human dosing. First-in-human trials are expected in the first half of 2027.
Key Points
- Lean mass fell to 6% of weight lost versus 22% alone
- Fat comprised 93% of weight loss in combination arm
- Single dose cut active Activin E 97% at week 8
Longevity Analysis
Weight reduction and functional longevity diverge when skeletal muscle is sacrificed alongside fat; lean tissue governs glucose disposal, metabolic rate, fall resistance and late-life independence. Targeting Activin E reframes pharmacological weight loss as a question of body composition quality rather than scale weight, preserving the contractile tissue that drives energy production and structural resilience. The extended half-life matters practically — infrequent dosing lowers the behavioral burden that determines whether any intervention is sustained long enough to alter trajectory, though these remain primate data with human trials still ahead.
Original published by LT Wire.